Rodman & Renshaw Initiates Coverage of Quince Therapeutics with a Buy
Published . Updated .
Fintel reports that on September 24, 2026, Rodman & Renshaw initiated coverage of Quince Therapeutics (NASDAQGS:QNCX) with a Buy recommendation.Prior to this rating action, the stock's pre-action close and latest close were both recorded at $30.15 on September 23, 2026. Quinc
Directly affected
- No company is named in this report.
Indirectly affected
- QNCX QUINCE THERAPEUTICS INC COM PA
GA selected QNCX as a RELATED security because its canonical security name directly matches this event's themes: therapeutics, quince. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| QNCX | — | — | — | — | — | — | — |
Fintel reports that on September 24, 2026, Rodman & Renshaw initiated coverage of Quince Therapeutics (NASDAQGS:QNCX) with a Buy recommendation.Prior to this rating action, the stock's pre-action close and latest close were both recorded a…
Source: Nasdaq Markets
How far Quince Therapeutics (QNCX) has moved since 24 Sep 2026
Since the first closing price after “Rodman & Renshaw Initiates Coverage of Quince Therapeutics with a Buy,” Quince Therapeutics (QNCX) is +3.05%. The S&P 500 fund (SPY) is -0.62% over the same days, a +3.66% difference versus the market.
Who gains and who loses around Quince Therapeutics (QNCX)
Companies carried with this story
- QNCX Quince Therapeutics
In “Rodman & Renshaw Initiates Coverage of Quince Therapeutics with a Buy,” Quince Therapeutics (QNCX) is linked, with no stored direction, medium confidence. Reason on file: GA selected QNCX as a RELATED security because its canonical security name directly matches this event's themes: therapeutics, quince. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Quince Therapeutics (QNCX)
“Rodman & Renshaw Initiates Coverage of Quince Therapeutics with a Buy” (24 Sep 2026) reaches Quince Therapeutics (QNCX) through this story.
For Quince Therapeutics (QNCX), the reason on file says GA selected QNCX as a RELATED security because its canonical security name directly matches this event's themes: therapeutics, quince. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Quince Therapeutics (QNCX)
QNCX traded between 26.23 and 36.26 across 12 sessions. The latest close on file is 31.30.
A simple score for Quince Therapeutics (QNCX)
14 out of 100
“Rodman & Renshaw Initiates Coverage of Quince Therapeutics with a Buy” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.